Sanofi US (@SanofiUS) header
Sanofi US (@SanofiUS) profile picture

Sanofi US

@SanofiUS

An R&D driven, AI-powered biopharma company committed to improving lives. For U.S. residents only. Interactions must comply with terms: https://nitter.cf/t.co/D3HnfO1Ymt

 Morristown, NJ
sanofi.us
Joined August 2010
  • Tweets18.4K
  • Following5.5K
  • Followers79.2K
Sanofi US retweeted
Sanofi (@sanofi) profile picture
Sanofi
@sanofi14h
Our Q3 2026 results are now available. Read the full press release for detailed insights: spkl.io/60137ZJ1J #SanofiResults $SAN $SNY
Q3 2026 Results

ALT Q3 2026 Results

5
1
13
3,030
We’ve added a new teammate to help keep the conversation around COVID-19 awareness in play.🏀 Together, we’re encouraging individuals at increased risk of COVID-19 illness to stay informed and speak with their healthcare providers. Learn more: spkl.io/60007pAOq
Image from Sanofi US (@SanofiUS)
1
1
6
888
Sanofi US retweeted
Sanofi (@sanofi) profile picture
Sanofi
@sanofiOct 1
#NEWS: We’ve announced an expansion of our global Alliance with @Regeneron to add multiple next-generation, long-acting antibodies to our joint immunology portfolio. Read more here: spkl.io/60177pWkN
Sanofi and Regeneron expand global Alliance with multiple next-generation antibodies\n

ALT Sanofi and Regeneron expand global Alliance with multiple next-generation antibodies\n

3
3
23
2,956
Pickleball is the fastest-growing sport in the US, and older adults are the MVPs. 🏓 But aging can increase risk from COVID-19, potentially leaving them sidelined. So, we’re partnering with @USAPickleball to help bring education: spkl.io/60107RcTy
4
1
697
Protection against serious respiratory syncytial virus lung infection is important for all babies entering their first RSV season. Discover which celebrity mom is joining us in our mission to help families learn how they can help protect their babies: spkl.io/60127RPd6
Image from Sanofi US (@SanofiUS)
577
The @US_FDA has approved our #MultipleMyeloma treatment, offering patients and providers a new subcutaneous treatment option. Read more about the approval ⬇️ spkl.io/60167Hsb8
Breaking news: FDA approves our subcutaneous multiple myeloma treatment

ALT Breaking news: FDA approves our subcutaneous multiple myeloma treatment

1
2
657
The @US_FDA granted accelerated approval for a treatment for #Type1Diabetes. Learn more ⬇️ spkl.io/60197DZQP
FDA grants accelerated approval to a T1D treatment

ALT FDA grants accelerated approval to a T1D treatment

2
2
611
Our new drug application for our first-in-class investigational oral molecule for type 3 Gaucher disease (GD3) has been accepted for priority review by the @US_FDA. Learn more: spkl.io/6010769NK
The FDA has granted priority review for our investigational oral molecule for type 3 Gaucher disease

ALT The FDA has granted priority review for our investigational oral molecule for type 3 Gaucher disease

2
1
1
518
Today at #ATS we presented for the first time, data that our investigational treatment for #AATD met all primary and key secondary endpoints. These findings reinforce our commitment to innovation for people living with this rare disease ⬇️ spkl.io/6018AhDCw
Positive data on AATD shared for the first time at ATS 2026

ALT Positive data on AATD shared for the first time at ATS 2026

1
3
541
At Digestive Disease Week, we’re sharing late-breaking results from our phase 4 study in adults with eosinophilic esophagitis (EoE), a progressive disease that can cause narrowing of the esophagus. Learn more here: spkl.io/6013AA7NU @Regeneron
Late-breaking phase 4 data in EoE presented at Digestive Disease Week 2026

ALT Late-breaking phase 4 data in EoE presented at Digestive Disease Week 2026

2
1
2
533
Sanofi US retweeted
Sanofi (@sanofi) profile picture
Sanofi
@sanofiApr 23
Our Q1 2026 results are now available. See the press release for more details: spkl.io/6014AfHOC #SanofiResults $SAN $SNY
Image from Sanofi (@sanofi)
2
7
20
2,220
The @US_FDA has approved our medicine for certain children aged 2-11 years with uncontrolled chronic spontaneous urticaria (CSU), a chronic skin disease. Read more: spkl.io/6015AfGH7
Our medicine for certain children with chronic spontaneous urticaria is now FDA approved

ALT Our medicine for certain children with chronic spontaneous urticaria is now FDA approved

4
605
The @US_FDA has approved a treatment for eligible young children with #Type1Diabetes. With this approval, we hope to better support these young T1D patients and their families. Learn more ⬇️ spkl.io/6015AfBwU
Image from Sanofi US (@SanofiUS)
3
3
557
#NEWS: COMPARE study presented at #ESCMIDGlobal2026: head-to-head tolerability comparison of a protein-based and an mRNA COVID-19 vaccine. Learn more ⬇️ spkl.io/6013A4sAV
New COVID-19 vaccine tolerability data unveiled at ESCMID

ALT New COVID-19 vaccine tolerability data unveiled at ESCMID

5
1
530
Proud to announce Sanofi is an Official Supporter of @FIFAWorldCup Boston 2026! With ~5K employees & our largest US site in MA, we're all in for Commonwealth. Science meets community on the world's biggest stage! 🌍 Learn more: spkl.io/6017AaJmx
Sanofi Becomes Official Boston World Cup 2026 Host City Supporter

ALT Sanofi Becomes Official Boston World Cup 2026 Host City Supporter

3
2
8
808
The @US_FDA has approved our medicine as the first and only medicine for allergic fungal rhinosinusitis (AFRS) in certain adults and children aged 6 years and older. Learn more: spkl.io/6018AvQG2 CC: @Regeneron
FDA approves our medicine for certain adults and children 6 years and older with AFRS

ALT FDA approves our medicine for certain adults and children 6 years and older with AFRS

1
4
11
1,292
Our investigational BTK inhibitor for the potential treatment of wAIHA was granted Breakthrough Therapy Designation by @US_FDA and Orphan Drug by @MHLWitter_en in Japan, highlighting our commitment to advancing therapies for #RareDiseases with significant unmet need.
Breaking news: Investigational therapy for wAIHA granted Breakthrough Therapy designation in the US, Orphan Drug in Japan

ALT Breaking news: Investigational therapy for wAIHA granted Breakthrough Therapy designation in the US, Orphan Drug in Japan

2
2
5
1,070
Read more ⬇️ spkl.io/6015At6cD
1
1
499
Phase 3 study results of our investigational oral therapy for Fabry disease and type 3 Gaucher disease are now available. Discover more about our ongoing #RareDisease research. ⬇️ spkl.io/6015ASU2l
Breaking news in Gaucher and Fabry disease

ALT Breaking news in Gaucher and Fabry disease

2
2
3
743
Sanofi US retweeted
Sanofi (@sanofi) profile picture
Sanofi
@sanofiJan 29
Our Q4 and full-year 2025 results are now available. Learn more: spkl.io/6016AqNnO #SanofiResults $SAN $SNY
Image from Sanofi (@sanofi)
1
6
1
17
2,310
Load more